Spyre Therapeutics (SYRE) risk factors, FY2024 10-K

Risks Related to Our Financial Condition and Capital Requirements

1. 01We will need to raise additional capital, and if we are unable to do so when needed, we will not be able to continue as a going concern
2. 02Any of these events could have a material adverse effect on our business, operating results and prospects. Even if successful in raising new capital, we could be limited in the amount of capital we raise due to investor demand restrictions placed on the amount of capital we raise or other reasons
3. 03We have never generated any revenue from product sales and may never be profitable
4. 04We have historically incurred losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future
5. 05Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights

Risks Related to Discovery, Development and Commercialization

1. 06We face competition from entities that have developed or may develop programs for the diseases addressed by our product candidates
2. 07collaborator must conduct extensive nonclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our programs and future product candidates
3. 08We are substantially dependent on the success of our three most advanced programs, SPY001, SPY002 and SPY003, alone or in combination, and our current and planned clinical trials of such programs may not be successful
4. 09permitted to market or promote these programs, or any other programs, before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals
5. 10If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates may be delayed and our expenses may increase and, as a result, our stock price may decline
6. 11Any drug delivery device that we potentially use to deliver our product candidates may have its own regulatory, development, supply and other risks
7. 12Our approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline of programs with commercial value
8. 13Development of combination therapies may present more or different challenges than development of monotherapies
9. 14If we encounter difficulties enrolling participants in our current and future clinical trials, our clinical development activities could be delayed or otherwise adversely affected
10. 15Preliminary, “topline” or interim data from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures
11. 16the general patient population and by medical personnel. Any of these occurrences could harm our business, financial condition, results of operations and prospects significantly
12. 17We may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success
13. 18Some of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue
14. 19We are conducting and may conduct future clinical trials for our programs at sites outside the United States, and the FDA may not accept data from trials conducted in such locations

Risks Related to Government Regulation

1. 20We may not be able to meet requirements for the chemistry, manufacturing and control of our programs
2. 21Our product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated
3. 22We may face difficulties from healthcare legislative reform measures and other changes in law
4. 23Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties
5. 24Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such product candidates at competitive prices, which would seriously harm our business
6. 25Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any
7. 26A breakthrough therapy, fast track, or other expedited designation for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval

Risks Related to Our Intellectual Property

1. 27Our ability to obtain and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage
2. 28We may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and in-licenses
3. 29We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products
4. 30We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
5. 31Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
6. 32Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 33We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
8. 34We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
9. 35Patent terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time
10. 36Our technology licensed from various third parties may be subject to retained rights

Risks Related to Our Reliance on Third Parties

1. 37We currently rely on our collaborations and licensing arrangements with third parties, including Paragon, for a substantial portion of our discovery capabilities and in-licenses

Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business

1. 38In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth
2. 39We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
3. 40Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
4. 41Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all
5. 42Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
6. 43Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
7. 44If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
8. 45We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition
9. 46We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions
10. 47We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments

Risks Related to Our Common Stock

1. 48The market price of our common stock has historically been volatile, and the market price of our common stock may decline in the future
2. 49Moreover, the capital markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock
3. 50Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
4. 51We do not anticipate that we will pay any cash dividends in the foreseeable future
5. 52Future sales of shares by existing stockholders could cause our stock price to decline
6. 53Future sales and issuances of equity and debt could result in additional dilution to our stockholders
7. 54Our principal stockholders own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval
8. 55We may become exposed to costly and damaging liability claims, either when testing our programs in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims
9. 56Litigation costs and the outcome of litigation could have a material adverse effect on our business
10. 57We continue to incur significant costs and demands upon management as a result of complying with the laws and regulations regulating public companies
11. 58We are no longer a “smaller reporting company” within the meaning of the Securities Act and as a result we are or will be subject to certain enhanced disclosure requirements which will require us to incur significant expenses and expend time and resources
12. 59delisting proceedings by the stock exchange on which our common shares are listed, or sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources
13. 60If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline
14. 61If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock may be negatively affected
15. 62As a public company, we incur significant legal, accounting, insurance, and other expenses, and our management and other personnel have and will need to continue to devote a substantial amount of time to compliance initiatives resulting from operating as a public company